Frank C. Dougherty

995 total citations
23 papers, 745 citations indexed

About

Frank C. Dougherty is a scholar working on Hematology, Nephrology and Genetics. According to data from OpenAlex, Frank C. Dougherty has authored 23 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 9 papers in Nephrology and 5 papers in Genetics. Recurrent topics in Frank C. Dougherty's work include Erythropoietin and Anemia Treatment (16 papers), Dialysis and Renal Disease Management (9 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Frank C. Dougherty is often cited by papers focused on Erythropoietin and Anemia Treatment (16 papers), Dialysis and Renal Disease Management (9 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Frank C. Dougherty collaborates with scholars based in Switzerland, United States and Spain. Frank C. Dougherty's co-authors include Ulrich Beyer, Bruno Reigner, Paul Jordan, Francesco Locatelli, H Schmutzler, Sylvie Opatrná, Richard A. Robson, Iain C. Macdougall, Anatole Besarab and Iain C. Macdougall and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Cardiology and American Journal of Kidney Diseases.

In The Last Decade

Frank C. Dougherty

23 papers receiving 708 citations

Peers

Countries citing papers authored by Frank C. Dougherty

Since Specialization

Citations

This map shows the geographic impact of Frank C. Dougherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank C. Dougherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank C. Dougherty more than expected).

Fields of papers citing papers by Frank C. Dougherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank C. Dougherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank C. Dougherty. The network helps show where Frank C. Dougherty may publish in the future.

Co-authorship network of co-authors of Frank C. Dougherty

This figure shows the co-authorship network connecting the top 25 collaborators of Frank C. Dougherty. A scholar is included among the top collaborators of Frank C. Dougherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank C. Dougherty. Frank C. Dougherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mortality and Cardiovascular Morbidity Associated with Haemoglobin Levels: A Pooled Analysis of Randomised Controlled Trials 2014 ·Nephron Clinical Practice ·Francesco Locatelli, Angel de Francisco, Gilbert Deray, Danilo Fliser, G. Armstrong, Frank C. Dougherty, Patricia Ehrhard	14
2	C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis 2011 ·Nephrology Dialysis Transplantation ·Simon D. Roger, Francesco Locatelli, Rainer P. Woitas, Martine Laville, Sheldon W. Tobe, Robert Provenzano, Thomas A. Golper, (unknown), H. Y. Lee, Kwan‐Dun Wu, Michał Nowicki, Andrea Ladányi, (unknown), Ulrich Beyer, Frank C. Dougherty	39
3	Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial 2010 ·Nephrology Dialysis Transplantation ·Fernando Carrera, Charmaine E. Lok, Angel de Francisco, Francesco Locatelli, Johannes F.E. Mann, Bernard Canaud, Peter G. Kerr, Iain C. Macdougall, Anatole Besarab, Giuseppe Villa, (unknown), Bruno Van Vlem, Shruti Jolly, Ulrich Beyer, Frank C. Dougherty, (unknown)	56
4	C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease 2010 ·Clinical Nephrology ·Francesco Locatelli, Johannes F.E. Mann, Jean‐Claude Aldigier, (unknown), Rebecca J. Schmidt, Bruno Van Vlem, Władysław Sułowicz, Frank C. Dougherty, Ulrich Beyer	19
5	C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study 2009 ·Hemodialysis International ·M. Kessler, Alberto Martínez‐Castelao, Kostas C. Siamopoulos, Giuseppe Villa, Bruce Spinowitz, Frank C. Dougherty, Ulrich Beyer	20
6	C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis 2008 ·Clinical Journal of the American Society of Nephrology ·Iain C. Macdougall, Rowan G. Walker, Robert Provenzano, Fernando de Álvaro, (unknown), (unknown), Francesco Locatelli, Frank C. Dougherty, Ulrich Beyer	79
7	The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A. 2008 ·Current Medical Research and Opinion ·Viera Kupčová, Jan Šperl, (unknown), Paul Jordan, Frank C. Dougherty, Bruno Reigner	3
8	Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol‐Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration¹ 2007 ·The Journal of Clinical Pharmacology ·Steven Fishbane, (unknown), (unknown), Paul Jordan, Frank C. Dougherty, Bruno Reigner	26
9	Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial 2007 ·American Journal of Kidney Diseases ·Marian Klinger, (unknown), Vassilis Vargemezis, Anatole Besarab, Władysław Sułowicz, Trevor Gerntholtz, Kazimierz Ciechanowski, Frank C. Dougherty, Ulrich Beyer	48
10	Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease 2007 ·Clinical Therapeutics ·Anatole Besarab, Moro O. Salifu, N M Lunde, Vinod Bansal, Steven Fishbane, Frank C. Dougherty, Ulrich Beyer	32
11	Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration 2007 ·Current Medical Research and Opinion ·Francesco Locatelli, Giuseppe Villa, Ángel Francisco, A Albertazzi, Horacio J. Adrogué, Frank C. Dougherty, Ulrich Beyer, (unknown)	51
12	The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. 2007 ·PubMed ·Robert Provenzano, Anatole Besarab, Iain C. Macdougall, David H. Ellison, Alexander P. Maxwell, (unknown), Marian Klinger, Piotr Rutkowski, Ricardo Correa‐Rotter, Frank C. Dougherty, (unknown)	42
13	Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease 2006 ·Clinical Journal of the American Society of Nephrology ·Iain C. Macdougall, Richard A. Robson, Sylvie Opatrná, (unknown), (unknown), Paul Jordan, Frank C. Dougherty, Bruno Reigner	143
14	Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study 2006 ·International Journal of Clinical Practice ·Ángel Francisco, Władysław Sułowicz, Marian Klinger, Stanisław Niemczyk, Vassilis Vargemezis, Fabien Métivier, Frank C. Dougherty, Delphine Oguey, (unknown)	31
15	CERA (Continuous Erythropoiesis Receptor Activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies 2004 ·Journal of Clinical Oncology ·Frank C. Dougherty, Bruno Reigner, Paul Jordan, (unknown)	11
16	CERA (Continuous Erythropoiesis Receptor Activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies 2004 ·Journal of Clinical Oncology ·Frank C. Dougherty, Bruno Reigner, Paul Jordan, (unknown)	3
17	Imaging of acute myocardial infarction by magnetic resonance tomography (MRT) using the paramagnetic relaxation substance gadolinium-DTPA 1989 ·Cardiovascular Drugs and Therapy ·(unknown), Roland Felix, Oliver Danne, Frank C. Dougherty, H Schmutzler	15
18	Limitation of Infarct Size 1989 ·H Schmutzler, Wolfgang Rutsch, Frank C. Dougherty	2
19	Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment 1987 ·The American Journal of Cardiology ·H. Eichstädt, Roland Felix, Mathias Langer, (unknown), Frank C. Dougherty, (unknown), H Schmutzler	16
20	32 Scintigraphic Demonstration of Reduction in Left Ventricular Hypertrophy During Therapy with Penbutolol 1984 ·Journal of Hypertension ·(unknown), (unknown), (unknown), (unknown), Frank C. Dougherty, H Schmutzler	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact